{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:46:37Z","timestamp":1793025997672,"version":"4.5.0"},"reference-count":9,"publisher":"American Medical Association (AMA)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:p>This Viewpoint explains the genetic association between Alzheimer disease and Down syndrome and the negative impact of excluding people with Down syndrome from clinical trials on treatment for Alzheimer disease.<\/jats:p>","DOI":"10.1001\/jama.2023.22924","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T16:33:45Z","timestamp":1700670825000},"page":"2157","source":"Crossref","is-referenced-by-count":46,"title":["Down Syndrome in a New Era for Alzheimer Disease"],"prefix":"10.1001","volume":"330","author":[{"given":"Michael S.","family":"Rafii","sequence":"first","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"},{"name":"Catalan Foundation for Down Syndrome, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"jvp230145r1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"jvp230145r2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"jvp230145r3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","article-title":"Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia.","volume":"20","author":"Fortea","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"jvp230145r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12910","article-title":"Association of Alzheimer disease with life expectancy in people with Down syndrome.","volume":"5","author":"Iulita","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"jvp230145r5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jalz.2017.03.007","article-title":"Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer\u2019s disease.","volume":"13","author":"Carmona-Iragui","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"3","key":"jvp230145r6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations.","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"jvp230145r7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.7326\/M20-4986","article-title":"COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults.","volume":"174","author":"Clift","year":"2021","journal-title":"Ann Intern Med"},{"issue":"5","key":"jvp230145r8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.v92.5","article-title":"Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease.","volume":"92","author":"Joseph-Mathurin","year":"2022","journal-title":"Ann Neurol"},{"issue":"1","key":"jvp230145r9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(22)00408-2","article-title":"Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer\u2019s disease: a cross-sectional study.","volume":"22","author":"Boerwinkle","year":"2023","journal-title":"Lancet Neurol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2812402\/jama_rafii_2023_vp_230145_1701364723.92763.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T16:25:24Z","timestamp":1702398324000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2812402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":9,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.22924","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,12]]}}}